Introduction

ADHD is a neurodevelopmental condition which manifests as cognitive and behavioural deficits. It is characterised by the core symptoms of persistent hyperactivity, impulsiveness and inattention. As well as presence of core symptoms identified, there must be clear evidence of psychological, social and/or educational or occupational impairment plus some impairment in two or more settings (home, at work, social, occupational).

As their brains mature, a significant proportion of adolescents will acquire the necessary skills to be able to manage without medication. However, some adolescents will still endure significant impairment due to ADHD, and will continue to need medication during the transition into adulthood, and during adult life.

ADHD is thought to be a persistent condition and a diagnosis, should only be made by a Specialist Psychiatrist or appropriately qualified healthcare professional with training and expertise in the diagnosis of ADHD.
For a diagnosis of ADHD, symptoms of hyperactivity/impulsivity and/or inattention should:

- Meet the diagnostic criteria DSM-5 or ICD-10 (hyperkinetic disorder) and
- Cause at least moderate psychological, social and/or educational or occupational impairment based on interview and/or direct observation in multiple settings and
- Be pervasive, occurring in 2 or more important settings including social, familial, educational and/or occupational settings.
- As part of the diagnostic process, include an assessment of the person’s needs, coexisting conditions, social, familial and educational or occupational circumstances and physical health.

NICE guidelines on the treatment of ADHD recommend that drug treatment of ADHD should form part of a comprehensive treatment programme that focuses on psychological, behavioural and educational or occupational needs.

See NICE guideline 87: Attention deficit hyperactivity disorder: diagnosis and management [https://www.nice.org.uk/guidance/ng87](https://www.nice.org.uk/guidance/ng87) for further details.

**Guidance Overview**

The remit of this guideline is to provide guidance on the shared care of adults who may be prescribed Atomoxetine, Dexamfetamine, Lisdexamfetamine and Methylphenidate in the following scenarios:

1) Continuation of therapy via a shared care guideline for adult patients who have been newly diagnosed with ADHD and who have been initiated on treatment by the Secondary care Specialist either directly or after referral to a Tertiary centre.
2) Continuation of therapy via a shared care guideline for “existing” adult patients who have been under the care of a Tertiary centre (e.g. Maudsley) and who have now been transferred back to the care of a local Secondary care Specialist.
3) Continuation of therapy via a shared care guideline for patients who have been prescribed ADHD medication under the Children and Adolescent Mental Health service (CAHMS) and who have now been transferred to the adult service.
This shared care guideline excludes:

1. Treatment of children and young people (6-17 years)
2. Treatment of children under 6 years
3. Treatment of adults ≥ 65 yrs - Refer to the Adults and Older Persons service

**Treatment of ADHD in Adults**

NICE Guideline 87 states the following with respect to the treatment of ADHD in Adults:-

- Offer medication to adults with ADHD if their ADHD symptoms are still causing a significant impairment in at least one domain* after environmental modifications** have been implemented and reviewed.

  * Domain refers to areas of function, e.g. interpersonal relationships, education and occupational attainment, and risk awareness. (Ref NICE NG 87, pg 63)
  ** Environmental Modifications are changes made to physical environment in order to minimise the impact of a person's ADHD on their day-to-day life e.g. changes to seating arrangements, changes to lighting and noise optimising work or education to have shorter periods of focus with movement breaks etc. (Ref NICE NG 87 pg 63)

- Consider non-pharmacological treatment for adults with ADHD who have:
  - Made an informed choice not to have medication
  - Difficulty adhering to medication
  - Found medication to be ineffective or cannot tolerate it.

- Consider non-pharmacological treatment in combination with medication for adults with ADHD who have benefited from medication but whose symptoms are still causing a significant impairment in at least one domain.

NICE Guideline 87 states the following with respect to the Medication Choice for ADHD in Adults:-

- Offer lisdexamfetamine or methylphenidate as first-line pharmacological treatment for adults with ADHD.
- Consider switching to lisdexamfetamine for adults who have had a 6-week trial of methylphenidate at an adequate dose but have not derived enough benefit in terms of reduced ADHD symptoms and associated impairment.
Consider switching to methylphenidate for adults who have had a 6-week trial of lisdexamfetamine at an adequate dose but have not derived enough benefit in terms of reduced ADHD symptoms and associated impairment.

Consider dexamfetamine for adults whose ADHD symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile.

Offer atomoxetine to adults if:
- they cannot tolerate lisdexamfetamine or methylphenidate or
- their symptoms have not responded to separate 6-week trials of lisdexamfetamine and methylphenidate, having considered alternative preparations and adequate doses.

Do not offer guanfacine without advice from a tertiary ADHD service.

To assess efficacy, the following rating scales could be used: Conners’ Adult ADHD Rating Scales (CAARS), the Strengths and Weaknesses of ADHD and Normal Behaviour Scale (SWAN), the SNAP-IV Rating Scale revision of Swanson, Nolan and Pelham (SNAP), ADHD Rating Scale – IV DuPaul et al, Adult Rating Scale (ARS), Current Symptom Scales (CSS), Adult ADHD Self-Report Scales (ASRS).

**Referral and Assessment Process**

**New Adult patients identified by GP as having possible ADHD**

- GP to refer to local Adult Psychiatric Specialist (ELFT) for initial assessment. If drug therapy is indicated, the ELFT specialist will initiate therapy. (NB: In more complex cases, the ELFT specialist may refer to a tertiary centre e.g. The Maudsley for advice prior to initiating therapy).*
- The local Adult Psychiatric Specialist (ELFT) who is initiating therapy should discuss with the patient and their family or carers (if applicable) about treatment options, including medication, treatment aims, available options, medication and alternative/additional interventions, side effects and the monitoring protocol.
- The possibility of stopping medication and reasons should also be discussed.
- Care can be transferred from local Adult Psychiatric Specialist to the patient’s GP via a shared care agreement once the patient has been established on a stable dose.
*Under this treatment pathway, there should be no direct transfer of care between the tertiary centre and the GP. Luton CCG will not fund referral from ELFT to the Maudsley Hospital as this is outside of the Luton CCG commissioned service contract with ELFT.*

Existing adult patients who have been under the care of a Tertiary centre and who have now been transferred back to the care of a local Secondary care Specialist

- Tertiary centre Specialist to discuss with the patient and their family or carers (if applicable) about continuation of treatment and arrange for the transfer of care to the local Secondary care Adult Psychiatric service. (ELFT).
- ELFT Specialist to accept the transfer of care from the Tertiary Centre and to initiate a shared care agreement for ongoing prescribing and monitoring with the patients GP.

CAMHS patients who transition into adult services

- CAMHS to inform Secondary care Adult Psychiatric services of the details and history of the patient who is approaching his/her 18th birthday and who has been identified as someone who may require on-going support with ADHD.
- CAMHS to inform the GP any decision to stop or alter the treatment plan prior to transition to adult services.
- ELFT Specialist to initiate a shared care agreement for ongoing prescribing and monitoring with the patients GP once patient has been transitioned into adult services.
- Should on-going prescription of psychostimulants be considered necessary, the patient should be advised of the need for safe storage to prevent diversion and potential abuse. Patients should be reminded that although medication is not licensed in adult ADHD, it may continue to be effective.

Only adolescents who show clear improvement with ADHD medication should be considered for on-going treatment as adults.

**Shared Care Responsibilities**

The aim of this document is to provide information to allow patients to be managed safely via transfer of prescribing across the Primary and Secondary care interface. It

assumes a partnership and an agreement between a hospital specialist, GP and the patient/carer and also sets out responsibilities for each party.

The intention to share care should be explained to the patient by the Specialist and accepted by the patient. Once, agreement has been reached with the patient, the Specialist should contact the GP and invite them to participate in a shared care arrangement. Agreement to share care will be assumed unless the GP advises otherwise. (NB: If a GP is not able to participate fully with the shared care agreement, they are under no obligation to do so. In such an event, the total clinical responsibility for the patient for the diagnosed condition of ADHD will remain with the Specialist team.) The CCG may be contacted to facilitate shared care with a primary care GP. Under this shared care agreement, patients will be under regular follow up and this provides an opportunity to discuss drug therapy. Intrinsic to the shared care agreement is that the prescribing doctor should be appropriately supported by a system of communication and co-operation in the management of patients.

The doctor who prescribes the medicine has clinical responsibility for the drug and the consequences of its use

SUMMARY OF ADULT PSYCHIATRIC SPECIALIST RESPONSIBILITIES

- For newly diagnosed adult patients, or where there has been a change in medication, carry out baseline assessments (see appendix 1), initiate treatment and prescribe until patient is stable. NICE recommends lisdexamfetamine or methylphenidate as first-line choices. Where more than one agent is considered suitable, the product with the lowest acquisition cost should be considered.
- The Adult Psychiatric Outpatient clinic will accept the transfer of patients from CAMHS who are approaching their 18th birthday and require on-going support and medication to manage their ADHD.
- The Adult Psychiatric Outpatient clinic will accept the transfer of patients who are being transferred from Tertiary care back to Secondary care.
- Request shared care with GP once patient is stable
- Send written correspondence to GP, ensuring that the dose and frequency of medication is clearly documented. If prescribing long acting Methylphenidate, prescribe by brand name (as different brands are not interchangeable).
- The Adult Psychiatric outpatient clinic will review the patient regularly and liaise with the GP should treatment be varied or discontinued.

The Adult Psychiatric outpatient clinic should advise female patients at the onset of treatment or at first visit (if transferred from another team / Hospital) that if they wish to conceive or if they become pregnant while taking medications that they should contact the Specialist as soon as possible to discuss treatment options.

Should medication no longer be considered necessary, the Adult Psychiatric outpatient clinic will advise the GP of an appropriate withdrawal regimen as ADHD medication should be withdrawn slowly. The patient’s on-going needs should be assessed by the CAS team of the adult CMHT.

Report adverse events to the CSM/MHRA via Yellow card located in BNF or online www.yellowcard.gov.uk

SUMMARY OF GP RESPONSIBILITIES

- Reply to the request for shared care as soon as practicable.
- To check that the patient is continuing to attend the outpatient clinics prior to re-authorisation of repeat prescriptions.
- Prescribe ADHD treatment at the dose recommended. If prescribing long acting Methylphenidate, prescribe by brand name (as different brands are not interchangeable).
- Adjust dose as advised by the specialist.
- If ADHD medication needs to be discontinued, contact the Specialist for advice on a withdrawal regimen (as ADHD medication needs to be withdrawn slowly) if not provided already.
- Monitor the patients overall health and well-being. (See Appendix 1)
- Contact the Specialist to discuss any significant changes in the patient’s condition.
- Inform Specialist of any emerging side effects.
- Inform the Specialist if there is suspicion of abuse of stimulant ADHD medication. Medication requests for longer than a month (e.g. covering holidays) should be discussed with the Specialist if necessary and can be issued at the prescriber’s discretion.
- Report adverse events to the Specialist and the MHRA/CSM via Yellow card located in the current BNF or online www.yellowcard.gov.uk
- Refer any patient who becomes pregnant or who wishes to plan a pregnancy to the Specialist team for an urgent review.
SUMMARY OF PATIENTS RESPONSIBILITIES

- Report to the specialist or GP if he or she does not have a clear understanding of the treatment.
- Share any concerns in relation to treatment with stimulants or Atomoxetine.
- Inform specialist or GP of any other medication being taken, including over-the-counter products.
- Report any adverse effects to specialist or GP whilst taking ADHD medication.
- To contact the Specialist team as soon as possible if a patient becomes pregnant or who wishes to plan a pregnancy.

Physical Health Monitoring

Routine blood tests and ECGs are not currently recommended unless there is a clinical indication.

For newly diagnosed adult patients, prior to starting drug treatment, the patient with ADHD should have a full pre-treatment assessment. (To be done by ELFT Specialist).

See appendix 1 for physical health monitoring standards.

ADHD medications

Methylphenidate or lisdexamfetamine are considered the stimulants of choice in the UK for adults with ADHD. Modified –release preparations of methylphenidate are preferable to immediate release preparations as they pose less risk of abuse and improve adherence. If Methylphenidate or lisdexamfetamine are ineffective or unacceptable, Atomoxetine or Dexamphetamine may be considered.

NB: Prescribers should note that ADHD drugs are not generally licensed for use in adult patients therefore, prescribing for adult patients is regarded as an “off label” use of a licensed product.

A summary of the licensed indications for each of the ADHD drugs is given below. For full up to date details and Licensing Information for ADHD drugs, clinicians should refer to individual Summary of Characteristics (SPCs) [www.medicines.org.uk/emc](http://www.medicines.org.uk/emc) or the most recent version of the electronic BNF; [https://bnf.nice.org.uk](https://bnf.nice.org.uk).

**Summary of Licensing Indications**

**Methylphenidate**
Methylphenidate is licensed for use in children aged 6 years of age and over. It is not licensed for initiation in adults per se however; it is acknowledged that it may be appropriate to continue treatment into adulthood. (Ref: Concerta XL® SPC)

**Atomoxetine**
Atomoxetine is licensed for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. When used in adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Atomoxetine should not be initiated when the verification of childhood ADHD symptoms is uncertain. (Ref: Strattera® SPC).

**Dexamfetamine**
Dexamfetamine is indicated as part of a comprehensive treatment programme for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17 years when response to previous Methylphenidate treatment is considered clinically inadequate.
Dexamfetamine is not licensed for use in adults. The safety and efficacy of Dexamfetamine in adults have not been established. (Ref: Amfexa® SPC)

**Lisdexamfetamine**
Lisdexamfetamine is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged 6 years and over when response to previous Methylphenidate treatment is considered clinically inadequate.
In adolescents whose symptoms persist into adulthood and who have shown clear benefit from treatment, it may be appropriate to continue treatment into adulthood. (Ref: Elvanse® SPC)
Prescribing Information:

General Points:

- For newly diagnosed adult patients commencing drug treatment, medication should be initiated by a Specialist Psychiatrist.
- Existing patients (either adults being transferred from Tertiary care to Secondary care or patients being transferred from CAMHS to adult services, medication should be continued as specified by Tertiary care Specialist / CAMHS team (as applicable).
- Clinicians should refer to the current BNF/SPC s and appendix 2 of this document for each drug for full information on dosage, contraindications / side effects / drug interactions etc.
- Drug treatment should be continued for as long as clinically effective and reviewed annually to assess need for continued treatment. Effects of missed doses, planned dose reductions, and periods of no treatment should be evaluated.
- Prescribers must follow the schedule 2 controlled drugs requirements when prescribing Methylphenidate, Dexamfetamine or Lisdexamfetamine as these drugs are schedule 2 controlled drugs. Atomoxetine is not classed as a schedule 2 controlled drug and normal prescription requirements apply.
- As drug costs are subject to change, GPs will be advised of the most cost-effective preparations via Scriptswitch or Optimise.

A prescription for Methylphenidate, Dexamfetamine or Lisdexamfetamine requires:

- the total quantity to be prescribed to be written in words and figures
- a maximum supply of 28 days
- signature in the prescriber's own hand writing where computer generated prescriptions are issued
- use of indelible ink if prescription handwritten, signed and dated by prescriber, name and address of patient, form and strength of preparation, dose and frequency in the prescriber's own handwriting
CONTACT DETAILS:

In case of any issues or queries with respect to shared care, GPs should initially contact the individual Specialist who has initiated therapy (details as stated on the initial clinical letter). Other points of contact are:

- Natasha Patel, Lead Pharmacist Luton & Bedfordshire (ELFT)
  Email: elft.pharmacyluton@nhs.net
  Tel: 01582 657564
- Dr Zelpha Kittler, Clinical Director, Bedfordshire (ELFT)
  Tel: 01234 299916
- Dr Farid Jabbar, Clinical Director, Luton (ELFT)
  Tel: 01582 707315
### SUMMARY OF MAIN FEATURES OF TREATMENT OPTIONS FOR ADHD – **THIS LIST IS NOT EXHAUSTIVE**

PRESCRIBERS SHOULD REFER TO THE ELECTRONIC BNF AND SPC FOR FULL CLINICAL DETAILS.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Atomoxetine</th>
<th>Methylphenidate</th>
<th>Dexamphetamine</th>
<th>Lisdexamfetamine mesilate</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Duration of action</strong></td>
<td>24 hours</td>
<td><strong>Concerta XL®</strong> - 12 hours <strong>Equasym XL®</strong> - 8 hours <strong>Standard Release Methylphenidate</strong> (e.g. <strong>Ritalin®, Medikinet®</strong>) &lt;12 hours</td>
<td>4-24 hours</td>
<td>Elvanse® – 8 hours</td>
</tr>
<tr>
<td><strong>Adverse Reactions</strong></td>
<td>Transient abdominal pain and lost appetite. Cold/flu symptoms, anorexia, early morning awakening, irritability, mood swings.</td>
<td>Transient decreased appetite, nervousness, Insomnia, headache, stomach ache. Drowsiness, dizziness, dyskinesia.</td>
<td>Insomnia, restlessness, irritability, euphoria, tremor, dizziness, headache and other symptoms of over-stimulation have been reported. Dry mouth, unwanted anorexia and other</td>
<td>Nausea, decreased appetite, vomiting, diarrhoea, dry mouth, abdominal cramps, dyspnoea, sleep disturbances, fics, aggression, headache, dizziness, drowsiness, mydriasis, labile mood, weight loss, pyrexia, malaise, growth restriction in; less commonly anorexia,</td>
</tr>
<tr>
<td>Special Precautions</td>
<td>Allergic reactions, hypertension, abdomen pain, nausea and vomiting. Dry mouth. TachyCARDIA, palpitations, arrhythmias, changes in blood pressure and heart rate. Rash, pruritus, urticaria, fever, arthralgia, alopecia. Cerebral arteritis, angina, hyperactivity, convulsions, psychosis, tics including Tourette syndrome, neuroleptic malignant syndrome, tolerance and dependence, growth retardation, reduced weight gain, blood disorders including leucopenia and thrombocytopenia, muscle cramps, visual disturbances, exfoliative dermatitis, erythema multiforme. gastro-intestinal symptoms, sweating, convulsions and cardiovascular effects (tachycardia, palpitations, minor increases in blood pressure). Isolated reports of cardiomyopathy associated with chronic amphetamine use. Drug dependence. Intracranial haemorrhages and a toxic hypermetabolic state. Rhabdomyolysis and renal damage. Psychosis/psychotic reactions, night terrors, nervousness, abdominal cramps, decreased blood pressure, altered libido and impotence, growth retardation, hyperpyrexia, mydriasis, hyperflexia, chest pain, confusion, panic states, aggressive behaviour, delirium, visual disturbance, choreoathetoid movements, tics and Tourette syndrome in predisposed individuals.</td>
<td>tachycardia, palpitation, hypertension, logorrhoea, anxiety, paranoia, restlessness, depression, dysphoria, dermatilomania, mania, hallucination, sweating, tremor, visual disturbances, sexual dysfunction, rash; very rarely angle-closure glaucoma; also reported cardiomyopathy, euphoria, seizures, central stimulants have provoked choreoathethoid movements and dyskinesia, and Tourette syndrome in predisposed individuals.</td>
<td>Abdominal pain, nausea and vomiting. Dry mouth. Tachycardia, palpitations, arrhythmias, changes in blood pressure and heart rate. Rash, pruritus, urticaria, fever, arthralgia, alopecia. Cerebral arteritis, angina, hyperactivity, convulsions, psychosis, tics including Tourette syndrome, neuroleptic malignant syndrome, tolerance and dependence, growth retardation, reduced weight gain, blood disorders including leucopenia and thrombocytopenia, muscle cramps, visual disturbances, exfoliative dermatitis, erythema multiforme.</td>
<td>Monitor blood pressure and full blood count; history of tachycardia, palpitation, hypertension, logorrhoea, anxiety, paranoia, restlessness, depression, dysphoria, dermatilomania, mania, hallucination, sweating, tremor, visual disturbances, sexual dysfunction, rash; very rarely angle-closure glaucoma; also reported cardiomyopathy, euphoria, seizures, central stimulants have provoked choreoathethoid movements and dyskinesia, and Tourette syndrome in predisposed individuals.</td>
</tr>
<tr>
<td>Contraindications</td>
<td>tachycardia, cardiovascular/cerebrovascular disease. Liver damage. Seizures. Suicidal thoughts/behaviour. Growth/development.</td>
<td>drug or alcohol dependence; psychosis; epilepsy; avoid abrupt withdrawal; pregnancy; GI narrowing (m/r preps).</td>
<td>history of dystonias. Tics, epilepsy, monitor growth, impaired kidney function or unstable personality. Psychotic children. Avoid abrupt withdrawal.</td>
<td>monitor for aggressive behaviour or hostility during initial treatment; history of drug or alcohol abuse; may lower seizure threshold (discontinue if seizures occur); tics and Tourette syndrome (use with caution)—discontinue if tics occur; monitor growth in children (see also below); susceptibility to angle-closure glaucoma; avoid abrupt withdrawal.</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Can be used in common ADHD comorbidities such as tics and Tourette’s and marked anxiety</td>
<td>YES</td>
<td>NO</td>
<td>NO</td>
<td>YES</td>
</tr>
<tr>
<td>Evidence of abuse potential</td>
<td>NO</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>----------------------------</td>
<td>----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>Controlled Drug</td>
<td>NO</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>Ongoing monitoring</td>
<td>Cardiovascular status should be regularly monitored with BP and pulse recorded after each adjustment of dose and then at least every 6 months. Current reference guidelines for hypertension should be followed.</td>
<td>Growth, psychiatric, and cardiovascular status should be continually monitored (see also section 4.4).  • Blood pressure and pulse should be recorded on a centile chart at each adjustment of dose and at least every six months.  • Development of <em>de novo</em> or worsening of pre-existing psychiatric disorders should be monitored at every adjustment of dose and then at least every six months and at every visit. Patients should be monitored for the risk of diversion, misuse, and abuse of Methylphenidate/ Dexamphetamine/ Lisdexamfetamine</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Appendix 1: Monitoring Standards (in line with current NICE guidance)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Frequency of monitoring/medication</th>
<th>Action</th>
<th>By Whom</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy</td>
<td>At each appointment and when doses are changed</td>
<td>Rating scales may be used</td>
<td>Specialist GP</td>
</tr>
<tr>
<td>Non-specific side effects</td>
<td>At each appointment</td>
<td>Review and monitor adverse effects, possible drug interactions, changes to medication regime, deteriorating behaviour. Communicate any relevant medical information to consultant/GP.</td>
<td>Specialist GP</td>
</tr>
<tr>
<td>Weight</td>
<td>Baseline, months 3 &amp; 6, then 6 monthly thereafter</td>
<td>Consider monitoring of BMI of adults with ADHD if there has been weight change as a result of their treatment, and changing medication (Refer back to Specialist) if weight change persists</td>
<td>Specialist – baseline and months 3 &amp; 6 GP – 6 monthly</td>
</tr>
<tr>
<td>Pulse &amp; Blood Pressure</td>
<td>Baseline, before and after dose change and then 6 monthly thereafter</td>
<td>Sustained resting tachycardia, arrhythmia or clinically significant high systolic blood pressure after two measurements, consider dose reduction and refer to adult physician /specialist</td>
<td>Specialist – baseline GP – before and after dose change and every 6 months</td>
</tr>
<tr>
<td>Full Blood Count (FBC)</td>
<td>Baseline only if indicated(Methylphenidate)</td>
<td>Low threshold for repeat FBC rather than routine e.g. recurrent infections, purpuric rash or based on medical history</td>
<td>GP</td>
</tr>
<tr>
<td>Cardiovascular risk assessment</td>
<td>Baseline, Throughout therapy</td>
<td>To include: enquiry about a history of cardiac symptoms such as syncope (fainting), breathlessness, palpitations, or congenital cardiac abnormalities, family diagnosis of cardiovascular disease/sudden cardiac death before the age of 40 years</td>
<td>Specialist GP</td>
</tr>
<tr>
<td>ECG</td>
<td>Only if known or suspected history</td>
<td>Referral to cardiologist</td>
<td>Specialist GP</td>
</tr>
<tr>
<td><strong>Liver Function</strong></td>
<td>Throughout therapy (Atomoxetine)</td>
<td>Be vigilant for abdominal pain, unexplained nausea, malaise, darkening of urine or jaundice. Routine testing of LFTs not recommended</td>
<td>Specialist GP</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td><strong>Suicidal thinking and self-harming behaviour</strong></td>
<td>During the initial months or after a change of dose (Atomoxetine)</td>
<td>Patients and carers should be warned about the potential for suicidal thinking and self-harming behaviour</td>
<td>Specialist GP, Parents or carers</td>
</tr>
<tr>
<td><strong>Risk assessment of substance misuse (diversion)</strong></td>
<td>Baseline, Throughout therapy</td>
<td>Enquire about known substance use in patient or that of close family member or carer. Concerns about requests for frequent prescriptions deemed unnecessary should be communicated to consultant/specialist</td>
<td>Specialist GP</td>
</tr>
<tr>
<td><strong>Sexual dysfunction (Atomoxetine)</strong></td>
<td>Throughout therapy</td>
<td>Be aware that young people and adults with ADHD may develop sexual dysfunction (i.e. erectile and ejaculatory dysfunction) as potential adverse effects of atomoxetine.</td>
<td>Specialist GP</td>
</tr>
<tr>
<td><strong>Changes in sleep patterns</strong></td>
<td>Throughout therapy</td>
<td>Monitor changes in sleep pattern (for example, with a sleep diary) and adjust medication accordingly.</td>
<td>Specialist</td>
</tr>
<tr>
<td><strong>Seizures</strong></td>
<td>Throughout therapy</td>
<td>If a person with ADHD develops new seizures or a worsening of existing seizures, GP to refer back to Specialist for review of ADHD medication and to stop any medication that might be contributing to the seizures. After investigation, the ADHD medication may be cautiously reintroduced if it is unlikely to be the cause of the seizures.</td>
<td>Specialist GP</td>
</tr>
<tr>
<td><strong>Tics</strong></td>
<td>Throughout therapy</td>
<td>If a person taking stimulants develops tics, Specialist to consider whether: - The tics are related to the stimulant (tics naturally wax and wane) <strong>and</strong> - The impairment associated with the tics outweighs the benefits of ADHD</td>
<td>Specialist</td>
</tr>
</tbody>
</table>
### APPENDIX 2: MEDICATION TABLE SUMMARY

For full up to date details and Licensing Information for ADHD drugs, clinicians should refer to individual Summary of Characteristics (SPCs) www.medicines.org.uk/emc or the most recent version of the electronic BNF www.bnf.org/products/bnf-online/ https://bnf.nice.org.uk/

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Methylphenidate Immediate-release tablets</th>
<th>Methylphenidate modified-release tablets</th>
<th>Atomoxetine capsules</th>
<th>Lisdexamfetamine capsules</th>
<th>Dexamfetamine tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indication &amp; Dose</td>
<td><strong>Unlicensed:</strong> Initial: 5mg 2 or 3 times a day. Titrate against symptoms and side effects at weekly intervals. Max: 100mg daily in up to 4 divided doses</td>
<td><strong>Unlicensed:</strong> Initial: As per immediate release tablets, Using an equivalent dose. If initiating with Equasym® XL, 100mg daily(before breakfast) Max 100mg daily Usually given once daily, but not more than twice daily</td>
<td><strong>Unlicensed:</strong> Initial: As per immediate release tablets, Using an equivalent dose. If initiating with Concerta® XL, use 18mg daily, adjusted at weekly intervals. Max 108mg daily Usually given once daily, but not more than twice daily</td>
<td><strong>Unlicensed:</strong> Initial: As part of a comprehensive treatment programme for ADHD in adults who have shown clear benefit from treatment in childhood 40mg/day minimum of 7 days, then titrate as required. Usual maintenance dose 80-100mg/day.</td>
<td><strong>Unlicensed:</strong> Initial: 5mg twice a day. Titrate against symptoms and side effects, increasing at weekly intervals as required. Max 60mg/day in 2-4 divided doses</td>
</tr>
<tr>
<td></td>
<td>Ritalin® 10mg Medikinet®5mg 10mg, 20mg tablets</td>
<td>Equasym® XL 10,20,30mg capsules Immediate – release component (30% of dose), modified release component (70% of dose)</td>
<td>Concerta® XL 18mg,.27mg, 36mg tablets Immediate – release component (22% of dose), modified release component (78% of dose)</td>
<td>Medikinet® XL 5mg,10mg, 20mg, 30mg, 40mg capsules Immediate release component (50% of the dose) modified release component (50% of dose)</td>
<td>Strattera® 10mg,18mg, 25mg,40mg,60mg, 80mg, 100mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Medikinet® XL 5mg,10mg, 20mg, 30mg, 40mg capsules Immediate release component (50% of the dose) modified release component (50% of dose)</td>
<td>Elvanse® 30mg,50mg,70mg</td>
<td>Dexamfetamine 5mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Approved by Medicines Management Committee 2018/ Beds & Luton Joint Prescribing Committee 2018
<table>
<thead>
<tr>
<th>Controlled Drug</th>
<th>Yes</th>
<th>Yes</th>
<th>Yes</th>
<th>Yes</th>
<th>No</th>
<th>Yes</th>
<th>Yes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical monitoring</td>
<td>See Appendix 1 Agree monitoring schedule with GP and consultant/specialist for adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interactions</td>
<td>For detailed information on interactions, cautions, contra-indications and side-effects, please refer to manufacturer’s Summary of Product Characteristics (SPC) <a href="http://www.medicines.org.uk">www.medicines.org.uk</a>, and also current BNF <a href="http://www.bnf.org/bnf">www.bnf.org/bnf</a></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Warfarin</td>
<td>Anti-convulsants</td>
<td>Selected tricyclic and serotonin reuptake inhibitors</td>
<td>Alcohol</td>
<td>Monoamine oxidase inhibitors</td>
<td>Anti-hypertensive drugs</td>
<td>Salbutamol CYP2D6 inhibitors (SSRI’s, quinidine, terbinafine)</td>
<td>Monoamine oxidase inhibitors</td>
</tr>
<tr>
<td>Adverse effects</td>
<td>Gastro-intestinal symptoms (stomach ache, affected appetite, dry mouth, nausea &amp; vomiting)</td>
<td>Psychiatric disorders (insomnia, abnormal behaviour, aggression, agitation, anxiety)</td>
<td>Nervous system disorders (dizziness, drowsiness, headache, dyskinesia)</td>
<td>Cardiac disorders (palpitations, tachycardia)</td>
<td>Gastro-intestinal Nervous system disorders Skin &amp; subcutaneous tissue</td>
<td>Gastro-intestinal Skin &amp; subcutaneous tissue</td>
<td>Gastro-intestinal Nervous system disorders Skin &amp; subcutaneous tissue Cardiac disorders</td>
</tr>
<tr>
<td>Cautions</td>
<td>Cardiovascular (hypertension &amp; Cerebrovascular disease) Psychiatric disorders Tics, history of seizures, aggressive behaviour, hostility or emotional lability, susceptible to angle closure glaucoma</td>
<td>Anorexia, history of cardiovascular disease or abnormalities, psychiatric disorders, aggressive behaviour, tics, Tourettes, susceptibility to angle closure glaucoma</td>
<td>Anorexia, mild hypertension, psychiatric disorders, aggressive behaviour, hostility during initiation, epilepsy, tics, Tourettes, susceptibility to angle closure glaucoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders (arthralgia) Skin &amp; subcutaneous tissue (rash, pruritus, urticarial, alopecia)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders (arthralgia) Skin &amp; subcutaneous tissue (rash, pruritus, urticarial, alopecia)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cautions</td>
<td>Cardiovascular (hypertension &amp; Cerebrovascular disease) Psychiatric disorders Tics, history of seizures, aggressive behaviour, hostility or emotional lability, susceptible to angle closure glaucoma</td>
<td>Anorexia, history of cardiovascular disease or abnormalities, psychiatric disorders, aggressive behaviour, tics, Tourettes, susceptibility to angle closure glaucoma</td>
<td>Anorexia, mild hypertension, psychiatric disorders, aggressive behaviour, hostility during initiation, epilepsy, tics, Tourettes, susceptibility to angle closure glaucoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contra-indications</td>
<td>Severe depression, suicidal ideation, anorexia nervosa, psychosis, uncontrolled bipolar disorder, hyperthyroidism, cardiovascular disease (including heart failure, cardiomyopathy, severe hypertension and arrhythmias), structural cardiac abnormalities, phaeochromocytoma, vasculitis, cerebrovascular disorders</td>
<td>Phaeochromocytoma Symptomatic cardiovascular disease (moderate to severe hypertension, advanced arteriosclerosis), hyperexcitability or agitation, hyperthyroidism</td>
<td>Cardiovascular disease (moderate to severe hypertension, structural cardiac abnormalities, advanced arteriosclerosis) hyperexcitability or agitation, hyperthyroidism, history of drug or alcohol abuse</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Approved by Medicines Management Committee 2018/ Beds & Luton Joint Prescribing Committee 2018
References:
1. NICE guideline 87: Attention deficit hyperactivity disorder: diagnosis and management https://www.nice.org.uk/guidance/ng87
2. NICE pathway for treatment of Adults with ADHD; Sep 2013 http://pathways.nice.org.uk/pathways/attention-deficit-hyperactivity-disorder
3. BNF – May 2015
5. British Association for Psychopharmacology 2014; Evidence based guidelines for the pharmacological management of attention deficit hyperactivity disorder :Update on recommendations
8. Barnet Enfield and Haringey Mental Health Trust shared care guidelines for Methylphenidate, Dexamfetamine and Atomoxetine in adults, 2010